Diabetes drug liraglutide linked to lower risk of cardiovascular events
[PRESS RELEASE 2018-12-06] Real world data from a large Nordic study shows that use of liraglutide, a drug for type 2 diabetes, is associated with a lower risk of myocardial infarction, stroke or cardiovascular death. The study, led by researchers from Karolinska Institutet in Sweden, is published in The Lancet Diabetes & Endocrinology.The number of patients with type 2 diabetes is increasing rapidly in the world. Cardiovascular disease is a serious complication of diabetes and represents a major cause of mortality in this patient group. Liraglutide, a diabetes medication, became